X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NRL-1 (diazepam) nasal spray act as inhibitory effects of gamma-aminobutyric acid (GABA), which is investigated for the treatment of epileptic seizures.
Lead Product(s): Diazepam
Therapeutic Area: Neurology Product Name: NRL-1
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2023
Details:
BF2.649 (pitolisant hydrochloride) is an antagonist/inverse agonist that binds to the histamine H3 receptor, an autoreceptor located in the presynaptic region of the histamine-containing neurons in the human brain that plays a critical role in regulating sleep and wake rhythm.
Lead Product(s): Pitolisant Hydrochloride
Therapeutic Area: Sleep Product Name: BF2.649
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2023
Details:
Aculys Pharma signed licensing agreement with Neurelis, for the development and commercialization of VALTOCO (diazepam nasal spray), approved by the FDA in the United States for the acute treatment of seizure clusters in patients with epilepsy six years of age and older.
Lead Product(s): Diazepam
Therapeutic Area: Neurology Product Name: Valtoco
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Neurelis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 26, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
